title: Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan.
abstract: The purpose of this work was to develop and statistically optimize nanotransfersomes for enhanced transdermal of valsartan vis-à-vis traditional liposomes. Nanotransfersomes bearing valsartan were prepared by conventional rotary evaporation method and characterized for various parameters including entrapment efficiency, vesicles shape, size, size distribution, and skin permeation. In vivo antihypertensive activity conducted on Wistar rats was also taken as a measure of performance of nanotransfersomes and liposomes. Nanotransfersomes proved significantly superior in terms of amount of drug permeated in the skin, with an enhancement ratio of 33.97 ± 1.25 when compared to rigid liposomes. This was further confirmed through a confocal laser scanning microscopy study. Nanotransfersomes showed better antihypertensive activity in comparison to liposomes by virtue of better permeation through Wistar rat skin. Finally, it could be concluded that the nanotransfersomes accentuates the transdermal flux of valsartan and could be used as a carrier for effective transdermal delivery of valsartan.
  
  
  BACKGROUND
  In this paper, the authors discuss the development and optimization of nanotransfersomes for enhanced transdermal of valsartan and demonstrate accentuated transdermal compared to standard preparations.
authors.affiliation: Faculty of Pharmacy, Hamdard University, New Delhi, India.
authors.forename: Abdul
authors.initials: A
authors.lastname: Ahad
authors.forename: Mohammed
authors.initials: M
authors.lastname: Aqil
authors.forename: Kanchan
authors.initials: K
authors.lastname: Kohli
authors.forename: Yasmin
authors.initials: Y
authors.lastname: Sultana
authors.forename: Mohammed
authors.initials: M
authors.lastname: Mujeeb
authors.forename: Asgar
authors.initials: A
authors.lastname: Ali
mesh_terms: D000279:Administration, Cutaneous; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D008081:Liposomes / Q000008:administration & dosage; D054118:Nanospheres / Q000008:administration & dosage* / Q000737:chemistry; D010316:Particle Size; D051381:Rats; D017208:Rats, Wistar; D013777:Tetrazoles / Q000008:administration & dosage* / Q000627:therapeutic use; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000959:Antihypertensive Agents; D008081:Liposomes; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine